Core Viewpoint - The collaboration between InSilico Medicine and Shenzhen Hengtai Biotechnology aims to accelerate the global development of ISM8969, a novel NLRP3 inhibitor for central nervous system diseases [1] Group 1: Partnership Details - InSilico Medicine and Shenzhen Hengtai Biotechnology have announced a joint development agreement for the ISM8969 project [1] - Under the agreement, InSilico Medicine grants Hengtai Biotechnology 50% rights for research, development, registration, production, and commercialization of ISM8969 globally [1] Group 2: Financial Aspects - InSilico Medicine is set to receive over HKD 500 million in upfront and milestone payments, including an upfront payment of HKD 78 million expected within 30 days of the agreement's effective date [1] Group 3: Development Responsibilities - InSilico Medicine will lead the early clinical development of ISM8969, including the submission of new drug clinical trial applications and the initiation of Phase I clinical trials for Parkinson's disease indications [1]
英矽智能盘中涨近5% 宣布与衡泰生物达成超5亿港元合作